[
  {
    "id": 301,
    "question": "Intracranial MCA severe stenosis what next",
    "option_a": "(DAPT) is correct because it directly targets the pathophysiology of platelet activation and subsequent thrombus formation in severe stenosis. Alternative options such as single antiplatelet therapy, anticoagulation, or immediate endovascular intervention are less suitable based on current evidence, which emphasizes the efficacy of DAPT. The marked answer (B) is incorrect because the evidence supports DAPT as the initial management strategy.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIntracranial stenosis of the MCA refers to a significant narrowing usually caused by atherosclerotic plaque, which predisposes patients to ischemic strokes. The core concept involves reducing the risk of thromboembolic events by stabilizing the atherosclerotic plaque and preventing platelet aggregation.\n\n**Pathophysiology**\n\nSevere intracranial stenosis leads to turbulent blood flow and endothelial injury, which can trigger platelet activation and thrombus formation. The SAMMPRIS trial provided evidence that dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces recurrent stroke risk by inhibiting platelet aggregation in these patients.\n\n**Clinical Correlation**\n\nPatients with severe MCA stenosis may present with transient ischemic attacks or stroke symptoms corresponding to the MCA territory (e.g., contralateral weakness, speech disturbances). The risk of recurrent events is high unless effective antithrombotic strategies are implemented.\n\n**Diagnostic Approach**\n\nDiagnosis typically involves non-invasive imaging such as CT/MRI to exclude infarcted tissue or hemorrhage, followed by vascular studies (MRA, CTA, or digital subtraction angiography) to assess the severity of stenosis. Differential diagnoses include dissection, vasculitis, and moyamoya disease, which are differentiated based on clinical history, imaging characteristics, and additional laboratory tests.\n\n**Management Principles**\n\nCurrent guidelines based on the SAMMPRIS trial recommend initiating DAPT (aspirin plus clopidogrel) for 90 days in patients with symptomatic severe intracranial stenosis. Risk factor modification, statin therapy, and lifestyle changes are also integral. For pregnant women, low-dose aspirin is typically considered safe, and while data on clopidogrel is limited, it may be used if the benefits outweigh the risks. Endovascular interventions remain a secondary option reserved for patients who fail medical therapy.\n\n**Option Analysis**\n\nOption A (DAPT) is correct because it directly targets the pathophysiology of platelet activation and subsequent thrombus formation in severe stenosis. Alternative options such as single antiplatelet therapy, anticoagulation, or immediate endovascular intervention are less suitable based on current evidence, which emphasizes the efficacy of DAPT. The marked answer (B) is incorrect because the evidence supports DAPT as the initial management strategy.\n\n**Clinical Pearls**\n\n1. DAPT with aspirin and clopidogrel is supported by evidence for reducing recurrent stroke in severe intracranial stenosis. 2. Early intensive medical management is often more beneficial than immediate invasive procedures. 3. Always assess and modify vascular risk factors concurrently.\n\n**Current Evidence**\n\nThe SAMMPRIS trial remains a cornerstone in the management of intracranial atherosclerotic disease, demonstrating that aggressive medical management with DAPT is superior to stenting in preventing recurrent strokes. Recent updates continue to support this approach, emphasizing individualized risk factor management and the potential role of newer antiplatelet agents.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 302,
    "question": "Minor stroke NIHSS 3 (left side decrease sensation, mild facial weakness) within the window what\u2019s next",
    "option_a": "(DAPT) is not the appropriate acute treatment because it does not address the clot directly as required in reperfusion strategies. Option B (tPA) is correct because it actively dissolves the clot and has been shown to improve outcomes in acute ischemic stroke. Option C (Aspirin alone) only serves a role in secondary prevention and lacks the efficacy in restoring perfusion during the acute phase.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn patients with a minor stroke (NIHSS 3) who are within the thrombolytic window, the primary goal is to rapidly restore cerebral perfusion. Although the symptoms might be mild, if they are potentially disabling, acute reperfusion therapy is warranted.\n\n**Pathophysiology**\n\nIschemic stroke results from an occlusive thrombus that obstructs blood flow. Intravenous tPA facilitates clot dissolution (thrombolysis), thereby restoring blood flow and reducing the infarct size. Even minor strokes, if affecting eloquent areas, can have a significant impact on quality of life.\n\n**Clinical Correlation**\n\nA patient presenting with decreased sensation and mild facial weakness, even with a low NIHSS score, may have deficits that are considered disabling if they impair daily activities. The timely administration of tPA can improve functional outcomes if given within the 4.5-hour therapeutic window.\n\n**Diagnostic Approach**\n\nEvaluation begins with a non-contrast head CT to exclude hemorrhage, followed by assessment of eligibility for thrombolytic therapy. Stroke mimics (migraine, seizure, hypoglycemia) should be considered but can typically be excluded based on clinical evaluation and imaging.\n\n**Management Principles**\n\nFirst-line management for eligible patients within the 4.5-hour window is intravenous thrombolysis (tPA). DAPT (aspirin plus clopidogrel) is recommended for secondary prevention but does not provide acute reperfusion. In pregnant patients, the use of tPA requires careful evaluation of risks versus benefits, though current literature suggests that, when indicated, tPA may be used in pregnancy on a case-by-case basis. In lactating women, tPA is generally considered safe because minimal transfer occurs into breast milk.\n\n**Option Analysis**\n\nOption A (DAPT) is not the appropriate acute treatment because it does not address the clot directly as required in reperfusion strategies. Option B (tPA) is correct because it actively dissolves the clot and has been shown to improve outcomes in acute ischemic stroke. Option C (Aspirin alone) only serves a role in secondary prevention and lacks the efficacy in restoring perfusion during the acute phase.\n\n**Clinical Pearls**\n\n1. Even minor strokes with disabling features warrant consideration for tPA if within the treatment window. 2. Quick imaging to differentiate ischemic from hemorrhagic events is critical before initiating thrombolysis. 3. Time is brain \u2013 the earlier the treatment, the better the potential outcome.\n\n**Current Evidence**\n\nRecent guidelines and trials, including those reflected in the American Heart Association/American Stroke Association recommendations, support the use of tPA for mild but disabling stroke symptoms in eligible patients. Ongoing research continues to refine patient selection for thrombolytic therapy, especially in cases presenting with low NIHSS scores.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 303,
    "question": "TIA found to have atrial flutter echo normal",
    "option_a": "(Factor Xa inhibitor) is correct because these agents have been shown to be effective in reducing the risk of embolic events in patients with atrial flutter. Other options such as antiplatelet therapy or rate control alone do not adequately reduce the thromboembolic risk associated with this arrhythmia.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAtrial flutter, similar to atrial fibrillation, predisposes patients to thrombus formation in the atria, which can embolize and cause transient ischemic attacks (TIAs) or strokes. The use of Factor Xa inhibitors is aimed at reducing this embolic risk.\n\n**Pathophysiology**\n\nIn atrial flutter, the organized but rapid atrial contractions lead to stasis in the atria, especially in the left atrial appendage. This stasis promotes clot formation. Factor Xa inhibitors, such as apixaban or rivaroxaban, block a key step in the coagulation cascade (the conversion of prothrombin to thrombin), thereby reducing clot formation and subsequent embolic events.\n\n**Clinical Correlation**\n\nPatients with atrial flutter can present with TIAs or embolic strokes even when structural heart evaluations (like an echocardiogram) are normal. This underscores the need for appropriate anticoagulation rather than just symptomatic management.\n\n**Diagnostic Approach**\n\nDiagnosis involves ECG to document atrial flutter, and often an echocardiogram to assess cardiac structure and function. Differential diagnoses include atrial fibrillation and other causes of cardioembolic stroke, such as valvular heart disease, which are differentiated based on the rhythm and imaging findings.\n\n**Management Principles**\n\nCurrent guidelines recommend the use of direct oral anticoagulants (DOACs), including Factor Xa inhibitors, for stroke prevention in patients with non-valvular atrial flutter or atrial fibrillation. In pregnancy, however, the use of Factor Xa inhibitors is generally avoided due to limited safety data; low-molecular-weight heparin is preferred. In lactating women, caution is advised, but many DOACs may be considered if the benefits outweigh the risks.\n\n**Option Analysis**\n\nOption A (Factor Xa inhibitor) is correct because these agents have been shown to be effective in reducing the risk of embolic events in patients with atrial flutter. Other options such as antiplatelet therapy or rate control alone do not adequately reduce the thromboembolic risk associated with this arrhythmia.\n\n**Clinical Pearls**\n\n1. Always consider the cardioembolic source in TIA when atrial flutter is present. 2. DOACs are preferred over vitamin K antagonists for non-valvular atrial arrhythmias in most patients due to their improved safety profile and ease of management. 3. Tailor anticoagulation strategies in pregnant or lactating patients carefully.\n\n**Current Evidence**\n\nRecent trials and updated guidelines continue to support the use of DOACs, including Factor Xa inhibitors, for stroke prevention in patients with atrial flutter/fibrillation. Ongoing studies are refining their risk-benefit profiles in special populations, including the elderly and those with co-morbid conditions.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 304,
    "question": "82 female with stroke NIHSS 20, BP 180/100, 3 hrs from symptoms onset, brain CT pic look okay no clear hypodensity but showed subtle early ischemic changes in BG, insular ribbon what to do next",
    "option_a": "(Labetalol) is incorrect because the patient\u2019s BP is below the threshold that necessitates acute lowering prior to thrombolysis; unnecessary BP reduction may compromise cerebral perfusion. Option B (Thrombolysis) is correct as the patient is within the 4.5",
    "option_b": "",
    "option_c": "(Thrombectomy) is not immediately indicated without further vascular imaging confirming a large vessel occlusion.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn acute ischemic stroke management, timely reperfusion therapy is critical. Intravenous thrombolysis (tPA) is indicated for patients presenting within 4.5 hours from symptom onset, provided there are no contraindications. Blood pressure management is an important precursor, but aggressive lowering is only necessary if the BP exceeds treatment thresholds.\n\n**Pathophysiology**\n\nAcute stroke results from an occlusive thrombus leading to cerebral ischemia. tPA works by enzymatically breaking down the clot and restoring blood flow. Elevated blood pressure is a common physiologic response in acute ischemia, and excessive lowering may compromise perfusion in the penumbra.\n\n**Clinical Correlation**\n\nAn 82-year-old female with an NIHSS of 20 and blood pressure of 180/100 mmHg is a candidate for tPA as her blood pressure is below the critical threshold of 185/110 mmHg. The CT scan, though showing subtle early ischemic changes, is not contraindicating thrombolysis. The primary goal is rapid reperfusion to salvage viable brain tissue.\n\n**Diagnostic Approach**\n\nThe diagnostic process involves CT imaging to exclude hemorrhage and confirm early ischemic changes, and vascular studies if large vessel occlusion is suspected. Differential diagnoses include hemorrhagic stroke and stroke mimics, but the clinical scenario and imaging findings support ischemic stroke.\n\n**Management Principles**\n\nFirst-line management for eligible acute ischemic stroke patients is intravenous thrombolysis with tPA. Blood pressure should be managed only if it exceeds 185/110 mmHg. In this case, since the BP is 180/100 mmHg, withholding BP lowering medications (like labetalol) is crucial to maintain cerebral perfusion. Mechanical thrombectomy is reserved for patients with confirmed large vessel occlusion. In pregnancy, tPA may be administered when the benefit outweighs potential risks, while in lactation, tPA is generally considered safe with minimal excretion in breast milk.\n\n**Option Analysis**\n\nOption A (Labetalol) is incorrect because the patient\u2019s BP is below the threshold that necessitates acute lowering prior to thrombolysis; unnecessary BP reduction may compromise cerebral perfusion. Option B (Thrombolysis) is correct as the patient is within the 4.5-hour window, with BP acceptable for tPA administration and imaging consistent with ischemia. Option C (Thrombectomy) is not immediately indicated without further vascular imaging confirming a large vessel occlusion.\n\n**Clinical Pearls**\n\n1. Do not lower blood pressure aggressively in acute ischemic stroke if it is below 185/110 mmHg prior to tPA. 2. tPA administration within the therapeutic window significantly improves outcomes even in elderly patients. 3. Early imaging and rapid clinical assessment are key to determining eligibility for reperfusion therapy.\n\n**Current Evidence**\n\nCurrent guidelines from the American Heart Association/American Stroke Association emphasize that patients with BP below 185/110 mmHg and within the 4.5-hour window should receive tPA. Recent studies continue to validate the safety and efficacy of thrombolysis in carefully selected elderly patients, reaffirming its role as the first-line therapy in acute ischemic stroke.",
    "exam_year": "2022",
    "exam_type": "Part II",
    "image_url": "page_23.png"
  },
  {
    "id": 305,
    "question": "Case of malignant MCA with mass effect and decreased level of consciousness found unresponsive, what will change outcomes",
    "option_a": "(Decompressive hemicraniectomy) is correct because it directly addresses the mass effect and intracranial hypertension, altering the course of the disease. Option B (Stroke admission) is vital for supportive care but does not reverse the mass effect. Option C (Hyperventilation) only provides transient reduction of ICP and may risk ischemia without improving long\u2010term outcomes.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nMalignant MCA infarction refers to a massive cerebral infarct in the middle cerebral artery territory that leads to severe cerebral edema and raised intracranial pressure. The central concept is that timely reduction of intracranial pressure through surgical means, specifically decompressive hemicraniectomy, can improve survival and functional outcomes.\n\n**Pathophysiology**\n\nAn occlusion of the MCA results in a large territory of brain tissue dying. This necrosis triggers both cytotoxic and vasogenic edema, which leads to a rapid rise in intracranial pressure and risk of herniation. Decompressive hemicraniectomy removes a part of the skull, allowing the swollen brain to expand and thus reducing the pressure on critical structures.\n\n**Clinical Correlation**\n\nClinically, these patients may present with decreased consciousness, signs of increased intracranial pressure (such as pupillary changes), and a risk for imminent brain herniation. Without intervention, the natural history is poor, with high mortality and morbidity.\n\n**Diagnostic Approach**\n\nDiagnosis is confirmed with neuroimaging (CT/MRI), which will demonstrate a large infarct with significant edema and mass effect. Differential diagnoses include hemorrhagic stroke, large territorial infarction with hemorrhagic transformation, and brain abscess. However, the imaging and clinical context of an acute malignant stroke help differentiate these conditions.\n\n**Management Principles**\n\nFirst-line management for patients with malignant MCA infarction in eligible populations (typically younger than 60 but individualized) is decompressive hemicraniectomy, optimally performed within 48 hours of stroke onset. Supportive treatment includes intensive care monitoring, osmotherapy, and maintaining adequate cerebral perfusion. In pregnant patients, surgical interventions are approached with careful multidisciplinary planning to balance maternal benefits with fetal safety. Non-surgical interventions like hyperventilation are only temporizing measures and insufficient as definitive management.\n\n**Option Analysis**\n\nOption A (Decompressive hemicraniectomy) is correct because it directly addresses the mass effect and intracranial hypertension, altering the course of the disease. Option B (Stroke admission) is vital for supportive care but does not reverse the mass effect. Option C (Hyperventilation) only provides transient reduction of ICP and may risk ischemia without improving long\u2010term outcomes.\n\n**Clinical Pearls**\n\n1. Early surgical intervention (within 48 hours) is crucial in malignant MCA infarction. 2. Non-surgical measures are supportive but do not change the natural history. 3. Decompressive hemicraniectomy has been shown in trials (e.g., DESTINY, HAMLET) to improve survival.\n\n**Current Evidence**\n\nRecent randomized controlled trials, including DESTINY and HAMLET, support the use of decompressive hemicraniectomy in appropriately selected patients with malignant MCA infarction, and current guidelines recommend timely surgical evaluation to improve survival and functional outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 306,
    "question": "Acute stroke treated with tPA pic showing tongue angio edema, patient stable but severely dysarthric, what to do",
    "option_a": "(Intubation) is incorrect in this context because the patient does not demonstrate active airway compromise. Option B (Steroid with antihistamine) is the appropriate first",
    "option_b": "",
    "option_c": "(ACE inhibitor with diuretics) is contraindicated because ACE inhibitors can exacerbate angioedema.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\ntPA-induced angioedema is a known complication of thrombolytic therapy in acute ischemic stroke. It typically manifests as localized swelling, most often involving the tongue or oropharyngeal structures, due to a bradykinin-mediated reaction.\n\n**Pathophysiology**\n\ntPA catalyzes the conversion of plasminogen to plasmin, which, besides breaking down clots, can increase bradykinin levels. Elevated bradykinin increases vascular permeability leading to angioedema. This reaction is usually localized and can be particularly concerning if it progresses to airway compromise.\n\n**Clinical Correlation**\n\nIn this scenario, the patient exhibits tongue angioedema with dysarthria but remains stable, with no signs of respiratory distress or imminent airway obstruction. Recognizing the early signs of angioedema is important to prevent potential progression to life-threatening airway compromise.\n\n**Diagnostic Approach**\n\nThe diagnosis is predominantly clinical, based on the temporal association with tPA administration and the appearance of tongue swelling. Differential diagnoses include ACE inhibitor-induced angioedema and allergic reactions to other medications. Airway assessment is paramount, with tools such as fiberoptic laryngoscopy used if needed.\n\n**Management Principles**\n\nFirst-line treatment for tPA-induced angioedema in a stable patient is the prompt administration of steroids combined with antihistamines. These agents work to reduce inflammation and limit the further progression of edema. Intubation is reserved for cases with clear evidence of airway compromise. For pregnant or lactating patients, low-dose steroids and certain antihistamines (those with a good safety profile) can be utilized, prioritizing airway security as the paramount concern.\n\n**Option Analysis**\n\nOption A (Intubation) is incorrect in this context because the patient does not demonstrate active airway compromise. Option B (Steroid with antihistamine) is the appropriate first-line treatment to address the inflammatory and bradykinin-mediated components. Option C (ACE inhibitor with diuretics) is contraindicated because ACE inhibitors can exacerbate angioedema.\n\n**Clinical Pearls**\n\n1. tPA-induced angioedema is often self-limited but requires close monitoring due to the risk of airway compromise. 2. Early administration of steroids and antihistamines can prevent further progression. 3. Airway management should be escalated only if there is evidence of respiratory distress.\n\n**Current Evidence**\n\nRecent studies and updated guidelines emphasize vigilant monitoring following tPA administration. Although the precise protocols may vary, the combination of steroids and antihistamines remains the cornerstone of management for tPA-induced angioedema in non-compromised patients.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 307,
    "question": "Long senario pt came with anyrism rupture of PcOm what you will do?",
    "option_a": "Cliping",
    "option_b": "Coiling",
    "option_c": "Decompressivw craniotomy",
    "option_d": "Amdission to stroke unit",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nA ruptured aneurysm, specifically in the posterior communicating artery (PcOM), is a neurosurgical emergency that typically presents as a subarachnoid hemorrhage. The key management goal is to secure the aneurysm promptly to prevent rebleeding.\n\n**Pathophysiology**\n\nThe rupture of an aneurysm leads to bleeding into the subarachnoid space, resulting in a sudden increase in intracranial pressure, irritation of the meninges, and potential vasospasm. Failure to secure the aneurysm places the patient at high risk for rebleeding, one of the main causes of morbidity and mortality.\n\n**Clinical Correlation**\n\nPatients with aneurysmal rupture often present with a sudden, severe headache (sometimes described as 'thunderclap headache'), neck stiffness, and altered mental status. Early intervention is crucial to stabilize the patient and prevent complications.\n\n**Diagnostic Approach**\n\nDiagnosis is typically made with a non-contrast head CT followed by CT angiography or digital subtraction angiography (DSA) to localize and characterize the aneurysm. Differential diagnoses include traumatic subarachnoid hemorrhage and perimesencephalic hemorrhage, which are differentiated based on imaging appearance and clinical history.\n\n**Management Principles**\n\nEndovascular coiling is generally preferred in many centers for treating ruptured aneurysms due to its less invasive nature and lower perioperative morbidity, provided the aneurysm\u2019s morphology is favorable. Microsurgical clipping remains an option when coiling is not feasible. In pregnant patients, endovascular procedures are performed with enhanced precautions to minimize fetal radiation exposure (using shielding and limiting contrast volume). Options like decompressive craniotomy or simple stroke unit admission are not definitive treatments for aneurysm rupture.\n\n**Option Analysis**\n\nOption A (Clipping) is a viable alternative but is more invasive compared to coiling. Option B (Coiling) is correct as it represents the preferred endovascular method in many cases for securing the aneurysm. Option C (Decompressive craniotomy) does not address the source of bleeding. Option D (Admission to a stroke unit) is supportive care but not a definitive treatment.\n\n**Clinical Pearls**\n\n1. Securing the aneurysm\u2014either via coiling or clipping\u2014is essential to prevent rebleeding. 2. Endovascular coiling is often preferred in anatomically favorable aneurysms. 3. Rapid identification and management are key to improving outcomes in subarachnoid hemorrhage.\n\n**Current Evidence**\n\nData from studies such as the International Subarachnoid Aneurysm Trial (ISAT) have demonstrated favorable outcomes with endovascular coiling compared to clipping in suitable patients. Current neurosurgical guidelines increasingly favor coiling as the first-line treatment in many cases of aneurysmal rupture.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 308,
    "question": "60 years old male pt DM/ HTN/ came with history of TiA for 10 min numbness and dysarthtia. NiHSs is 3. We have to calculate ABCD2 score. On examination ot still have numbness what you will give",
    "option_a": "aspirin",
    "option_b": "plavix",
    "option_c": "dual",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nTransient ischemic attacks (TIAs) are brief episodes of neurologic dysfunction caused by temporary cerebral ischemia. Risk stratification using tools like the ABCD2 score is essential to identify patients at higher risk for subsequent strokes and to guide antiplatelet therapy.\n\n**Pathophysiology**\n\nTIAs occur when there is a temporary interruption of blood flow to the brain, leading to transient neurological deficits without infarction on imaging. Patients with vascular risk factors\u2014such as diabetes, hypertension, and older age\u2014are at increased risk of repeated events due to underlying atherosclerotic disease.\n\n**Clinical Correlation**\n\nThis 60-year-old male with diabetes and hypertension has experienced a TIA characterized by brief episodes of numbness and dysarthria. The presence of residual symptoms (persistent numbness) alongside a moderate NIHSS score (3) suggests an elevated risk for recurrent stroke, necessitating aggressive secondary prevention.\n\n**Diagnostic Approach**\n\nEvaluation involves a thorough neurological exam supplemented by neuroimaging (CT/MRI) to rule out established infarction, as well as vascular imaging (carotid ultrasound, CT or MR angiography) to assess for significant stenosis. Differential diagnoses include seizure-related deficits, hypoglycemia, and migraine with aura.\n\n**Management Principles**\n\nCurrent guidelines recommend dual antiplatelet therapy (DAPT), typically with aspirin plus clopidogrel, for high-risk TIA patients or those with minor strokes (usually for 21-90 days) to reduce the risk of subsequent stroke. After this short-term period, patients are generally transitioned to single antiplatelet therapy. In pregnant or lactating patients, low-dose aspirin is generally considered safe, but clopidogrel requires careful risk-benefit analysis due to limited data.\n\n**Option Analysis**\n\nOption A (Aspirin alone) may offer some protection but is less effective than dual therapy in high-risk individuals. Option B (Clopidogrel alone) is not favored as monotherapy compared to the synergistic effect of dual therapy. Option C (Dual antiplatelet therapy) is correct as it has been shown to reduce early recurrent cerebrovascular events in patients with high-risk TIA, as supported by the CHANCE and POINT trials.\n\n**Clinical Pearls**\n\n1. A high ABCD2 score in TIA patients indicates a significantly increased risk of stroke. 2. Dual antiplatelet therapy is recommended for a limited duration in high-risk TIA patients to reduce recurrence. 3. Early identification and intervention in TIA can significantly alter stroke outcomes.\n\n**Current Evidence**\n\nRecent clinical trials (CHANCE, POINT) have demonstrated that short-term dual antiplatelet therapy significantly reduces the risk of recurrent stroke in patients with high-risk TIA or minor stroke. Current guidelines advocate using DAPT for a short duration (21-90 days) before transitioning to monotherapy to balance efficacy with bleeding risks.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 309,
    "question": "45 YO female came with SAH and found to have P-chom aneurysm what's next",
    "option_a": "Endovascular coiling",
    "option_b": "Surgical clipping",
    "option_c": "Observation",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSubarachnoid hemorrhage (SAH) secondary to a ruptured aneurysm is a neurological emergency. In this case, the aneurysm is located at the posterior communicating (P-com) segment, which is one of the common sites for berry aneurysms. The main management goal is to secure the aneurysm to prevent rebleeding.\n\n**Pathophysiology**\n\nA saccular (berry) aneurysm develops at a weak point in the arterial wall. Its rupture releases blood into the subarachnoid space, triggering a cascade of events including raised intracranial pressure, vasospasm, and hydrocephalus. Evidence from trials such as ISAT (International Subarachnoid Aneurysm Trial) has helped shape management choices between endovascular and surgical approaches.\n\n**Clinical Correlation**\n\nPatients typically present with a sudden 'thunderclap headache', loss of consciousness, or neurological deficits. A P-com aneurysm may also present with cranial nerve III palsy (ptosis and a 'down and out' eye) if it compresses the oculomotor nerve.\n\n**Diagnostic Approach**\n\nInitial evaluation includes a non\u2010contrast CT scan to identify SAH. If the CT is equivocal, a lumbar puncture is indicated. Digital subtraction angiography (DSA) or CT angiography (CTA) is used to localize and characterize the aneurysm. Differential diagnoses include traumatic SAH, perimesencephalic hemorrhage, and non-aneurysmal causes of SAH.\n\n**Management Principles**\n\nAccording to current guidelines, once an aneurysm is identified in a ruptured SAH, it must be secured emergently. Endovascular coiling is often first line if the aneurysm\u2019s size and morphology are favorable. If endovascular treatment is unsuitable due to anatomical constraints or if there are other complicating factors, surgical clipping is considered. In pregnancy or lactation, the decision must weigh the risks of radiation (for coiling) against surgical risks. Multidisciplinary discussions involving neurosurgery, neurointerventionalists, and obstetrics are essential to customize management.\n\n**Option Analysis**\n\nOption A (Endovascular coiling) is the correct next step because it is minimally invasive and supported by trials (ISAT) in appropriately selected patients. Option B (Surgical clipping) is an alternative when coiling is not feasible. Option C (Observation) is not acceptable given the high risk of rebleeding with unsecured aneurysms.\n\n**Clinical Pearls**\n\n\u2022 Timely securing of a ruptured aneurysm greatly reduces the risk of fatal rebleeding. \u2022 Endovascular coiling is preferred in many centers for aneurysms with favorable anatomy. \u2022 Always assess for potential vasospasm in the days following SAH.\n\n**Current Evidence**\n\nRecent updates and long\u2010term follow\u2010up from the ISAT study and other trials continue to support the use of endovascular coiling for aneurysms that are anatomically amenable, with a trend toward lower morbidity compared to clipping. Newer devices and techniques further expand the indications for endovascular treatment.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "id": 310,
    "question": "What to expect from O.A. infarction",
    "option_a": "Ipsilateral Horner",
    "option_b": "Ipsilateral hearing loss",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSubarachnoid hemorrhage (SAH) secondary to a ruptured aneurysm is a neurological emergency. In this case, the aneurysm is located at the posterior communicating (P-com) segment, which is one of the common sites for berry aneurysms. The main management goal is to secure the aneurysm to prevent rebleeding.\n\n**Pathophysiology**\n\nA saccular (berry) aneurysm develops at a weak point in the arterial wall. Its rupture releases blood into the subarachnoid space, triggering a cascade of events including raised intracranial pressure, vasospasm, and hydrocephalus. Evidence from trials such as ISAT (International Subarachnoid Aneurysm Trial) has helped shape management choices between endovascular and surgical approaches.\n\n**Clinical Correlation**\n\nPatients typically present with a sudden 'thunderclap headache', loss of consciousness, or neurological deficits. A P-com aneurysm may also present with cranial nerve III palsy (ptosis and a 'down and out' eye) if it compresses the oculomotor nerve.\n\n**Diagnostic Approach**\n\nInitial evaluation includes a non\u2010contrast CT scan to identify SAH. If the CT is equivocal, a lumbar puncture is indicated. Digital subtraction angiography (DSA) or CT angiography (CTA) is used to localize and characterize the aneurysm. Differential diagnoses include traumatic SAH, perimesencephalic hemorrhage, and non-aneurysmal causes of SAH.\n\n**Management Principles**\n\nAccording to current guidelines, once an aneurysm is identified in a ruptured SAH, it must be secured emergently. Endovascular coiling is often first line if the aneurysm\u2019s size and morphology are favorable. If endovascular treatment is unsuitable due to anatomical constraints or if there are other complicating factors, surgical clipping is considered. In pregnancy or lactation, the decision must weigh the risks of radiation (for coiling) against surgical risks. Multidisciplinary discussions involving neurosurgery, neurointerventionalists, and obstetrics are essential to customize management.\n\n**Option Analysis**\n\nOption A (Endovascular coiling) is the correct next step because it is minimally invasive and supported by trials (ISAT) in appropriately selected patients. Option B (Surgical clipping) is an alternative when coiling is not feasible. Option C (Observation) is not acceptable given the high risk of rebleeding with unsecured aneurysms.\n\n**Clinical Pearls**\n\n\u2022 Timely securing of a ruptured aneurysm greatly reduces the risk of fatal rebleeding. \u2022 Endovascular coiling is preferred in many centers for aneurysms with favorable anatomy. \u2022 Always assess for potential vasospasm in the days following SAH.\n\n**Current Evidence**\n\nRecent updates and long\u2010term follow\u2010up from the ISAT study and other trials continue to support the use of endovascular coiling for aneurysms that are anatomically amenable, with a trend toward lower morbidity compared to clipping. Newer devices and techniques further expand the indications for endovascular treatment.",
    "exam_year": "2022",
    "exam_type": "Part II"
  }
]